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METHOD: A literature review was conducted from
1966 to 1998 to search for all published studies that
aimed at increasing mammography compliance. Each in-
dividual study was examined in terms of its study design,
intervention given, study setting, sample size, compli-
ance, and effectiveness. Statistical analysis to compare ef-
fectiveness was conducted using Chi-Square test.
RESULTS: There were 16 studies identified. They were
all US studies from 1987 to 1994. Study duration was
from 3 to 36 months (median 12.0). The study locations
were inner city (19%), urban (69%), and rural (12%).
Sample size ranged from 63 to 4559 (medium 238). In-
terventions used can be grouped into four categories: mo-
bile van service (2), work-site mammography (4), re-
minder (8), and incentive (2), and their mean increase in
compliance rates was 33.0%, 23.8%, 23.0%, and 4.0%,
respectively. Statistical analysis for effective assessment in
descending order was as follow: mobile van service (RR 
3.74; 95% CI 2.50–5.59), reminder (RR  1.65; 95% CI
1.56–1.75), work-site mammography (RR  1.36; 95%
CI 1.23–1.51), and incentive programs (RR  1.14; 95%
CI 0.77–1.71).
CONCLUSIONS: Our preliminary analysis showed mo-
bile van service as the most effective intervention. How-
ever, since all type of programs could increase compli-
ance, their utility should be assessed based on the relative
costs and other constraints of the delivery system.
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With the isolation of the breast cancer susceptibility genes,
it is becoming possible to identify individuals who are at
substantially increased risk of developing breast cancer.
OBJECTIVES: The purpose of this study is to evaluate
the cost-effectiveness of genetic testing for breast cancer.
METHODS: A cost-effectiveness model was developed
to determine the impact of genetic testing for breast can-
cer. Data were obtained from medical literature. The tar-
get population of this analysis consisted of women age 30
to 34 who are the first-degree relatives of breast cancer
patients with strong family history. The cost analysis was
performed from the societal perspective, including direct
and indirect costs. All costs were converted to 1998 US
dollars. The results were presented as incremental cost
per life-year saved through genetic testing. All costs and
life-years were discounted to a present value using a 3%
annual discount rate. One-way sensitivity analysis was
used to assess the stability of the results when different
probabilities and assumptions were applied.
RESULTS: A genetic testing program started with 100
breast cancer patients with strong family history resulted
in saving 7.32 discounted life-years of their 150 at-risk
first-degree relatives compared to no testing. With the net
incremental cost at $289,236, the cost-effectiveness ratio
was $39,526 per life-year saved. Even when the parame-
ters were varied in the sensitivity analysis, the results
were robust.
CONCLUSIONS: On the basis of a range of assumptions
this model suggests that genetic testing of women who
have a strong family history of breast cancer may be cost-
effective. Studies that include the impact of genetic test-
ing on quality of life should be pursued in the future.
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OBJECTIVE: To determine the cost-effectiveness of screen-
ing versus no screening for retinopathy in Type I diabetics,
and secondly to determine the cost-effectiveness of screen-
ing every 6 months versus screening every 12 months.
METHODS: Data was compiled from previously pub-
lished articles. The diabetic population was divided into
two groups, one that received screening for diabetic retin-
opathy and one that did not. The group that received
screening were screened either every 6 months or 12
months and the development of diabetic retinopathy was
observed. The endpoint was the progression of the disease
to blindness. This study used the payer’s perspective and
hence only the direct costs of the screening procedure and
treatment of diabetic retinopathy were included in the cost
measures. The outcome measure was the number of sight
years saved as a result of timely screening and treatment.
RESULTS: For the cohort that did not receive screening
post diagnosis, the average total cost was $22,023/person
over 18 years. Total cost of screening and treating the pa-
tient was $8790 per person over 18 years. The total
6-month screening and treatment cost for the cohort that
received screening was $27,651 over 18 years and the
12-month screening cost was $53,257/person. The total
sight years saved for the 6-month and the 12-month screen-
ing was 5 years and 3 years, respectively.
CONCLUSION: Our results illustrate that screening the
patient for diabetic retinopathy is less costly than not
screening the patient. Also, the 6-month screening proce-
dure is significantly more cost-effective than the 12-month
procedure.
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